<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1.0"><title>Table of AEs of Special Interest adapted from https://insightsengineering.github.io/tlg-catalog/stable/tables/adverse-events/aet01_aesi.html — t_aesi_slide • autoslider.core</title><!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.7.1/jquery.min.js" integrity="sha512-v2CJ7UaYy4JwqLDIrZUI/4hqeoQieOmAZNXBeQyjo21dadnwR+8ZaIJVT8EE2iyI61OV8e6M8PP2/4hpQINQ/g==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><!-- Bootstrap --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous"><script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css"><script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet"><script src="../pkgdown.js"></script><meta property="og:title" content="Table of AEs of Special Interest adapted from https://insightsengineering.github.io/tlg-catalog/stable/tables/adverse-events/aet01_aesi.html — t_aesi_slide"><meta property="og:description" content="Table of AEs of Special Interest
adapted from https://insightsengineering.github.io/tlg-catalog/stable/tables/adverse-events/aet01_aesi.html"><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body data-spy="scroll" data-target="#toc">


    <div class="container template-reference-topic">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">autoslider.core</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="">0.0.1.9020</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav"><li>
  <a href="../reference/index.html">Reference</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Articles

    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu"><li>
      <a href="../articles/tutorial.html">Tutorial (Beginner)</a>
    </li>
  </ul></li>
<li>
  <a href="../news/index.html">Changelog</a>
</li>
      </ul><ul class="nav navbar-nav navbar-right"></ul></div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->



      </header><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header">
    <h1>Table of AEs of Special Interest adapted from https://insightsengineering.github.io/tlg-catalog/stable/tables/adverse-events/aet01_aesi.html</h1>

    <div class="hidden name"><code>t_aesi_slide.Rd</code></div>
    </div>

    <div class="ref-description">
    <p>Table of AEs of Special Interest
adapted from https://insightsengineering.github.io/tlg-catalog/stable/tables/adverse-events/aet01_aesi.html</p>
    </div>

    <div id="ref-usage">
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">t_aesi_slide</span><span class="op">(</span><span class="va">adsl</span>, <span class="va">adae</span>, <span class="va">aesi</span>, arm <span class="op">=</span> <span class="st">"ACTARM"</span>, grad_var <span class="op">=</span> <span class="st">"AETOXGR"</span><span class="op">)</span></span></code></pre></div>
    </div>

    <div id="arguments">
    <h2>Arguments</h2>


<dl><dt id="arg-adsl">adsl<a class="anchor" aria-label="anchor" href="#arg-adsl"></a></dt>
<dd><p>ADSL data set, dataframe</p></dd>


<dt id="arg-adae">adae<a class="anchor" aria-label="anchor" href="#arg-adae"></a></dt>
<dd><p>ADAE data set, dataframe.</p></dd>


<dt id="arg-aesi">aesi<a class="anchor" aria-label="anchor" href="#arg-aesi"></a></dt>
<dd><p>AESI variable which will act as a filter to select the rows required to create the table.
An example of AESI variable is CQ01NAM.</p></dd>


<dt id="arg-arm">arm<a class="anchor" aria-label="anchor" href="#arg-arm"></a></dt>
<dd><p>Arm variable, character, `"ACTARM"` by default.</p></dd>


<dt id="arg-grad-var">grad_var<a class="anchor" aria-label="anchor" href="#arg-grad-var"></a></dt>
<dd><p>Grading variable, character, `"AETOXGR"` by default.</p></dd>

</dl></div>
    <div id="value">
    <h2>Value</h2>
    <p>rtables object</p>
    </div>
    <div id="author">
    <h2>Author</h2>
    <p>Kai Xiang Lim (`limk43`)</p>
    </div>

    <div id="ref-examples">
    <h2>Examples</h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="va">adsl</span> <span class="op">&lt;-</span> <span class="va">eg_adsl</span></span></span>
<span class="r-in"><span><span class="va">adae</span> <span class="op">&lt;-</span> <span class="va">eg_adae</span></span></span>
<span class="r-in"><span><span class="va">adae_atoxgr</span> <span class="op">&lt;-</span> <span class="va">adae</span> <span class="op"><a href="https://magrittr.tidyverse.org/reference/pipe.html" class="external-link">%&gt;%</a></span> <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/mutate.html" class="external-link">mutate</a></span><span class="op">(</span>ATOXGR <span class="op">=</span> <span class="va">AETOXGR</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="fu">t_aesi_slide</span><span class="op">(</span><span class="va">adsl</span>, <span class="va">adae</span>, aesi <span class="op">=</span> <span class="st">"CQ01NAM"</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                                    A: Drug X    B: Placebo    C: Combination</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                                     (N=134)       (N=134)        (N=132)    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one AESI                                   97 (72.4%)    93 (69.4%)      99 (75.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of AESIs                                                                 396           380            465      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one AESI by worst grade                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 1                                                                          4 (3.0%)      3 (2.2%)           0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 2                                                                          6 (4.5%)      10 (7.5%)       7 (5.3%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 3                                                                         18 (13.4%)    14 (10.4%)      16 (12.1%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 4                                                                         15 (11.2%)    20 (14.9%)      18 (13.6%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 5 (fatal outcome)                                                         76 (56.7%)    70 (52.2%)      75 (56.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with study drug withdrawn due to AESI                    21 (15.7%)    15 (11.2%)      26 (19.7%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with dose modified/interrupted due to AESI               56 (41.8%)    63 (47.0%)      64 (48.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with treatment received for AESI                         91 (67.9%)    93 (69.4%)      95 (72.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with all non-fatal AESIs resolved                        23 (17.2%)    17 (12.7%)      19 (14.4%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one unresolved or ongoing non-fatal AESI   96 (71.6%)    100 (74.6%)     97 (73.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one serious AESI                           104 (77.6%)   101 (75.4%)     99 (75.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one related AESI                           99 (73.9%)    98 (73.1%)     102 (77.3%)  </span>
<span class="r-in"><span><span class="fu">t_aesi_slide</span><span class="op">(</span><span class="va">adsl</span>, <span class="va">adae</span>, aesi <span class="op">=</span> <span class="st">"CQ01NAM"</span>, arm <span class="op">=</span> <span class="st">"ARM"</span>, grad_var <span class="op">=</span> <span class="st">"AESEV"</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                                    A: Drug X    B: Placebo    C: Combination</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                                     (N=134)       (N=134)        (N=132)    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one AESI                                   97 (72.4%)    93 (69.4%)      99 (75.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of AESIs                                                                 396           380            465      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one AESI by worst grade                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Mild                                                                             4 (3.0%)      3 (2.2%)           0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Moderate                                                                        24 (17.9%)    24 (17.9%)      23 (17.4%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Severe                                                                          91 (67.9%)    90 (67.2%)      93 (70.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with study drug withdrawn due to AESI                    21 (15.7%)    15 (11.2%)      26 (19.7%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with dose modified/interrupted due to AESI               56 (41.8%)    63 (47.0%)      64 (48.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with treatment received for AESI                         91 (67.9%)    93 (69.4%)      95 (72.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with all non-fatal AESIs resolved                        23 (17.2%)    17 (12.7%)      19 (14.4%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one unresolved or ongoing non-fatal AESI   96 (71.6%)    100 (74.6%)     97 (73.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one serious AESI                           104 (77.6%)   101 (75.4%)     99 (75.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one related AESI                           99 (73.9%)    98 (73.1%)     102 (77.3%)  </span>
<span class="r-in"><span><span class="fu">t_aesi_slide</span><span class="op">(</span><span class="va">adsl</span>, <span class="va">adae_atoxgr</span>, aesi <span class="op">=</span> <span class="st">"CQ01NAM"</span>, grad_var <span class="op">=</span> <span class="st">"ATOXGR"</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                                    A: Drug X    B: Placebo    C: Combination</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                                     (N=134)       (N=134)        (N=132)    </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one AESI                                   97 (72.4%)    93 (69.4%)      99 (75.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of AESIs                                                                 396           380            465      </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one AESI by worst grade                                                              </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 1                                                                          4 (3.0%)      3 (2.2%)           0       </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 2                                                                          6 (4.5%)      10 (7.5%)       7 (5.3%)   </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 3                                                                         18 (13.4%)    14 (10.4%)      16 (12.1%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 4                                                                         15 (11.2%)    20 (14.9%)      18 (13.6%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   Grade 5 (fatal outcome)                                                         76 (56.7%)    70 (52.2%)      75 (56.8%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with study drug withdrawn due to AESI                    21 (15.7%)    15 (11.2%)      26 (19.7%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with dose modified/interrupted due to AESI               56 (41.8%)    63 (47.0%)      64 (48.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with treatment received for AESI                         91 (67.9%)    93 (69.4%)      95 (72.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with all non-fatal AESIs resolved                        23 (17.2%)    17 (12.7%)      19 (14.4%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one unresolved or ongoing non-fatal AESI   96 (71.6%)    100 (74.6%)     97 (73.5%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one serious AESI                           104 (77.6%)   101 (75.4%)     99 (75.0%)  </span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Total number of patients with at least one related AESI                           99 (73.9%)    98 (73.1%)     102 (77.3%)  </span>
<span class="r-in"><span></span></span>
</code></pre></div>
    </div>
  </div>
  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">
    <nav id="toc" data-toggle="toc" class="sticky-top"><h2 data-toc-skip>Contents</h2>
    </nav></div>
</div>


      <footer><div class="copyright">
  <p></p><p>Developed by Joe Zhu, Heng Wang, Yinqi Zhao, Bo Ci, Liming Li, Xiaoli Duan, Stefan Pascal Thoma, Miles Almond, Chenkai Lv.</p>
</div>

<div class="pkgdown">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

      </footer></div>






  </body></html>

